Futures point to the ASX opening fairly flat this morning on another busy day of reporting.

Today, the Bank of Queensland, IGO, Sandfire Resources and Harvey Norman will all release their results.

Here are some stocks to watch for your Thursday:

Invictus Energy (IVZ) has finished its mudgas analysis program, reaffirming the presence of light oil, wet gas condensate, and helium in its Mukuyu-1 well at its Cabora Bassa project in Zimbabwe.

“These results validate the presence of multiple hydrocarbon-bearing reservoirs in the Mukuyu-1/ST-1 well, as well as the company’s basin and geological models of the Cabora Bassa project,” IVZ Managing Director Scott Macmillan said.

“The Pebbly Arkose and Dande Formation reservoirs remain exploration targets for future drilling activity and will also be tested in the upcoming Mukuyu-2 well, which is on track to spud in September.”

IVZ shares last traded at 17 cents.

Also in the energy space, Pure Hydrogen (PH2) has secured a financing partner to fund a $125 million equipment finance facility to support the rental of hydrogen-powered prime movers and buses.

Once established, the facility will store and offer its Hydrogen Fuel Cell (HFC) trucks to its customers on a multi-year rental basis, inclusive of maintenance services and thesupply of hydrogen fuel.

The facility is expected to be up and running in early 2024.

PH2 shares last traded at 17 cents.

Neurotech International (NTI) has completed its phase I/II trial usingNTI164 in children diagnosed with paediatric autoimmune neuropsychiatric disorders.

The company has now dosed 15 paediatric patients with a daily oral treatment of NTI164over 12 weeks, and now all patients will continue to receive treatment under the extension phase of 54 weeks.

“Neuroinflammation is well characterised in PANDAS/PANS, where approved drug therapies are lacking and clinical trials are desperately needed…We look forward to reporting the clinical efficacy and safety of NTI164 in these patients over the 12-week study period,” NTI Executive Director Dr Thomas Duthy said.

Results of the clinical trial are expected in Mid to Late September 2023.

NTI shares last traded at 5 cents.

Meanwhile, Develop Global (DVP) has discovered extensive high-grade mineralisation at 42.9 per cent zinc equivalent outside the resource at its Woodlawn copper-zinc-silver project in NSW.

“These are very important because they show that mineralisation is higher grade and wider than outlined in the model, for example, grab samples averaged 18.4 per cent zinc equivalent versus an expected 14.3 per cent zinc equivalent,” DVP Managing Director Bill Beament said.

The find has prompted an update to the company’s mine plan this quarter and an update to its mineral resource estimate, which will be due in December.

DVP shares last traded at $2.80.

And Galileo Mining (GAL) has kicked off its first drill program north of its Castillo discovery at its Norseman project in WA.

“Within the same drill program, we will also be undertaking follow-up drilling at the Jimberlana North and South prospects where we have already shown that prospective sulphides occur,” GAL Managing Director Brad Underwood said.

The 4000-metre program is anticipated to take four weeks to complete, with assays expected in October.

GAL shares last traded at 42 cents.